JP2017537927A - がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用 - Google Patents

がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用 Download PDF

Info

Publication number
JP2017537927A
JP2017537927A JP2017529805A JP2017529805A JP2017537927A JP 2017537927 A JP2017537927 A JP 2017537927A JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017537927 A JP2017537927 A JP 2017537927A
Authority
JP
Japan
Prior art keywords
antibody
cancer
tumor
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017529805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537927A5 (enExample
Inventor
マイケル・ダロン・ロビンス
ロバート・エフ・グラジアノ
ナタリー・ベズマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2017537927A publication Critical patent/JP2017537927A/ja
Publication of JP2017537927A5 publication Critical patent/JP2017537927A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017529805A 2014-12-04 2015-12-03 がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用 Withdrawn JP2017537927A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462087489P 2014-12-04 2014-12-04
US62/087,489 2014-12-04
PCT/US2015/063585 WO2016090070A1 (en) 2014-12-04 2015-12-03 Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)

Publications (2)

Publication Number Publication Date
JP2017537927A true JP2017537927A (ja) 2017-12-21
JP2017537927A5 JP2017537927A5 (enExample) 2019-01-17

Family

ID=55022696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529805A Withdrawn JP2017537927A (ja) 2014-12-04 2015-12-03 がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用

Country Status (13)

Country Link
US (1) US20170355768A1 (enExample)
EP (1) EP3227335A1 (enExample)
JP (1) JP2017537927A (enExample)
KR (1) KR20170088984A (enExample)
CN (1) CN107249632A (enExample)
AU (1) AU2015358462A1 (enExample)
BR (1) BR112017011538A2 (enExample)
CA (1) CA2969665A1 (enExample)
EA (1) EA201791049A1 (enExample)
IL (1) IL252535A0 (enExample)
MX (1) MX2017007097A (enExample)
SG (1) SG11201704343SA (enExample)
WO (1) WO2016090070A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106008462A (zh) 2010-12-17 2016-10-12 诺华股份有限公司 一种alk抑制剂的结晶形式
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
MX2019005089A (es) * 2016-11-02 2019-09-10 Apexigen Inc Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso.
US20210155691A1 (en) * 2018-04-16 2021-05-27 Adaerata, Limited Partnership Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
AU772676B2 (en) 1998-12-23 2004-05-06 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
ATE254615T1 (de) 1999-02-22 2003-12-15 Biotechnolog Forschung Gmbh C-21 modifizierte epothilone
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
MXPA05006828A (es) 2002-12-23 2005-09-08 Wyeth Corp Anticuerpos contra pd-1, y sus usos.
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US6958115B2 (en) 2003-06-24 2005-10-25 The United States Of America As Represented By The Secretary Of The Navy Low temperature refining and formation of refractory metals
JP4361545B2 (ja) 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
AU2007281682B2 (en) 2006-08-07 2013-05-16 Abbvie Biotherapeutics Inc. Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
PT2068874E (pt) * 2006-08-07 2015-05-21 Abbvie Biotherapeutics Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP2012507555A (ja) 2008-10-31 2012-03-29 アボット バイオセラピューティクス コーポレイション 稀少疾患の治療における抗ｃｓ１抗体の使用
US20130058921A1 (en) 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
EP2493485A1 (en) 2009-10-30 2012-09-05 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
SG10201700698WA (en) 2012-05-15 2017-02-27 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Also Published As

Publication number Publication date
BR112017011538A2 (pt) 2018-03-13
EA201791049A1 (ru) 2017-10-31
IL252535A0 (en) 2017-07-31
EP3227335A1 (en) 2017-10-11
US20170355768A1 (en) 2017-12-14
MX2017007097A (es) 2017-09-05
CA2969665A1 (en) 2016-06-09
SG11201704343SA (en) 2017-06-29
WO2016090070A1 (en) 2016-06-09
KR20170088984A (ko) 2017-08-02
AU2015358462A1 (en) 2017-07-27
CN107249632A (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
US20250297028A1 (en) Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
KR102870759B1 (ko) 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
KR102867506B1 (ko) 퀴놀린 유도체 및 항체의 약물 조합
CN104470949A (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
US20160264670A1 (en) Immunotherapeutic dosing regimens and combinations thereof
JP2017537927A (ja) がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用
US20210154183A1 (en) Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
US20220143228A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
KR20230128271A (ko) 고형 암의 치료를 위한 her3 방사선면역요법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181129

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190509